Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2022 | Pooled analysis from the CRICKET and CAVE trials for the treatment of mCRC

Erika Martinelli • 14 Jul 2022
ESMO WCGIC 2022
Colorectal Cancer Gastrointestinal Cancer Antibodies Avelumab Cetuximab Irinotecan
CAVE

Erika Martinelli, MD, PhD, University of Campania Luigi Vanvitelli, Caserta, Italy, discusses the findings from an analysis of data pooled from the CRICKET (NCT02296203) and CAVE (NCT04561336) trials. The positive results of the rechallenge third-line treatment with cetuximab, such as the resulting median progression-free survival (PFS) of 3.9 months and median overall survival (OS) of 16.9 months, are discussed. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.

More from Erika Martinelli

2:06
Updates in colorectal cancer research from ESMO WCGIC 2022
Erika Martinelli • 14 Jul 2022
1:47
Updates on biomarkers of resistance to CRC treatment
Erika Martinelli • 14 Jul 2022
1:35
CRICKET and CAVE: cetuximab for the treatment of mCRC
Erika Martinelli • 14 Jul 2022

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals